Better prediction for effectiveness of paroxetine

April 13, 2017, Max Planck Society

A third of patients with depression do not respond to the first antidepressant medication prescribed. Currently, the only approach available is one of trial and error. In this study, Max Planck scientists have identified a biosignature able to distinguish patients who will and will not respond to treatment with the antidepressant paroxetine. This study is an important step forward in personalised medicine.

The therapeutic response to antidepressants varies considerably between with depression. About one third of the patients do not respond to the first prescribed antidepressant, an outcome only known after four to six weeks of continuous medication. It is not uncommon for these patients to have to undergo several rounds of with different antidepressants in order to find a suitable and dose. Aside from the associated costs, this situation results in lengthy suffering and an elevated risk of suicide for the patient.

Biosignatures able to predict the antidepressant treatment outcome for each patient would provide a precise medical approach to replace the current trial and error medication regimen. Biosignatures are objective biological measurements that are already used in other areas of medicine, but are absent in psychiatry. Such biosignatures would be of great value, allowing the treating psychiatrist to predict whether a patient will respond favourably to an antidepressant drug at the outset or during the early course of treatment.

Pathways in the neurons of the hippocampus as biosignature

Scientists around Chris Turck at the Max Planck Institute of Psychiatry in Munich, in collaboration with Marianne Müller at the University of Mainz, have used mice to delineate relevant molecular pathways characteristic for the response or non-response to the antidepressant paroxetine. In this study, the scientists profiled proteins and metabolites present in the hippocampus. They found that glutamate and ubiquitin-proteasome pathways are associated with the response to antidepressants. Glutamate is one of the major neurotransmitters and plays a central role in various brain functions. Ubiquitination is a quality control process critical for the removal of damaged proteins.

The suitable drug from the beginning

The scientists then looked to see if these pathways could be used to identify which patients would and would not respond to treatment. They took blood samples from patients with Major Depressive Disorder and found that the biosignature profiles were capable of stratifying the clinical antidepressant response. Importantly, they were able to distinguish antidepressant responder and non-responder patients prior to starting medication. "Predictive biosignatures for the antidepressant treatment response will reduce lengthy treatment ordeals for the patient because we will know the most suitable from the get go. This is a great step forward in the personalised medicine approach in psychiatry" concludes Dongik Park, the paper's first author. According to Chris Turck, "Biosignatures will also help in drug development by providing new target information. Additionally, they will be useful for clinical trials of novel antidepressants for patients suffering from treatment resistant depression."

Explore further: Brain scan before antidepressant therapy may predict response

More information: D I Park et al. Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems, Translational Psychiatry (2017). DOI: 10.1038/tp.2017.39

Related Stories

Brain scan before antidepressant therapy may predict response

January 24, 2017
A functional MRI brain scan may help predict which patients will respond positively to antidepressant therapy, according to a new study published in the journal Brain.

Blood test to personalize depression treatment for the first time

June 6, 2016
Scientists at King's College London have developed a blood test that accurately and reliably predicts whether depressed patients will respond to common antidepressants, which could herald a new era of personalised treatment ...

Antidepressants induce resilience and reverse susceptibility

February 2, 2017
When they work, antidepressant medications may take weeks or months to alleviate symptoms of depression. Progress in developing new and more effective antidepressant treatments has been limited, though a new study published ...

Arthritis drug boosts effectiveness of antidepressant medication, study finds

November 11, 2016
Giving severely depressed patients the arthritis drug celecoxib (Celebrex) dramatically boosted the effectiveness of their antidepressant medication, a Loyola study has found.

Antidepressant efficacy varies for depressive symptom clusters

February 28, 2017
(HealthDay)—Antidepressant treatment efficacy varies for empirically-defined clusters of symptoms, according to a study published online Feb. 22 in JAMA Psychiatry.

Biomarkers for antidepressant treatment response

September 20, 2012
(Medical Xpress)—Researchers from King's College London's Institute of Psychiatry (IoP) have identified new biomarkers for antidepressant treatment response, an important step towards developing personalised treatments ...

Recommended for you

Psychiatric disorders share an underlying genetic basis

June 21, 2018
Psychiatric disorders such as schizophrenia and bipolar disorder often run in families. In a new international collaboration, researchers explored the genetic connections between these and other disorders of the brain at ...

One year of school comes with an IQ bump, meta-analysis shows

June 21, 2018
A year of schooling leaves students with new knowledge, and it also equates with a small but noticeable increase to students' IQ, according to a systematic meta-analysis published in Psychological Science, a journal of the ...

Ketamine acts fast to treat depression and its effects last—but how?

June 21, 2018
In contrast to most antidepressant medications, which can take several weeks to reduce depressive symptoms, ketamine—a commonly used veterinary anesthetic—can lift a person out of a deep depression within minutes of its ...

Mindful movement may help lower stress, anxiety

June 21, 2018
Taking a walk may be a good opportunity to mentally review your to-do list, but using the time to instead be more mindful of your breathing and surroundings may help boost your wellbeing, according to researchers.

New study debunks Dale Carnegie advice to 'put yourself in their shoes'

June 21, 2018
Putting yourself in someone else's shoes and relying on intuition or "gut instinct" isn't an accurate way to determine what they're thinking or feeling," say researchers from Ben-Gurion University of the Negev (BGU), the ...

Brain tingles—first study of its kind reveals physiological benefits of ASMR

June 21, 2018
Autonomous sensory meridian response (ASMR) – the relaxing 'brain tingles' experienced by some people in response to specific triggers, such as whispering, tapping and slow hand movements – may have benefits for both ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.